CrkL functions as a nuclear adaptor and transcriptional activator in Bcr-Abl-expressing cells

Experimental Hematology

Volumn 28, Issue 3, 2000, Pages 305-310

  Rhodes, Jennifer ^a   York, Randall D ^a   Tara, David ^a   Tajinda, Katsu ^a   Druker, Brian J ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Bcr Abl; CrkL; Stat5

Indexed keywords

ADAPTOR PROTEIN; STAT5B PROTEIN;

ANIMAL CELL; ARTICLE; CELL STRAIN K 562; CONTROLLED STUDY; ELECTROPHORETIC MOBILITY; GENETIC TRANSFECTION; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; RAT;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; DNA-BINDING PROTEINS; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MILK PROTEINS; NUCLEAR PROTEINS; SIGNAL TRANSDUCTION; SRC HOMOLOGY DOMAINS; STAT5 TRANSCRIPTION FACTOR; TRANS-ACTIVATION (GENETICS); TRANS-ACTIVATORS; TUMOR CELLS, CULTURED;

EID: 0034012542     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(99)00148-4     Document Type: Article

References (34)

1. Nowell P.C., Hungerford D.A. A minute chromosome in human chronic granulocytic leukemia. Science. 132:1960;1497.
2. Rowley J.D. A new consistent abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and giemsa staining. Nature. 243:1973;290.
3. Heisterkamp N., Stephenson J.R., Groffen J., Hansen P.F., de Klein A., Bartram C.R., Grosveld G. Localization of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukemia. Nature. 306:1983;239.
4. Bartram C.R., de Klein A., Hagemeijer A., van Agthoven T., Geurts van Kessel A., Bootsma D., Grosveld G., Ferguson-Smith M.A., Davies T., Stone M., Heisterkamp N., Stephenson J.R.et al. Translocation of c-abl correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukemia. Nature. 306:1983;277.
5. Konopka J.B., Watanabe S.M., Witte O.N. An alteration of the human c-abl protein in K562 unmasks associated tyrosine kinase activity. Cell. 37:1984;1035.
6. Lugo T.G., Pendergast A.M., Muller A.J., Witte O.N. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 247:1990;1079.
7. Daley G.Q., Van Etten R.A., Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science. 247:1990;824.
8. Kelliher M.A., McLaughlin J., Witte O.N., Rosenberg N. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc Natl Acad Sci U S A. 87:1990;6649.
9. Nichols G.L., Raines M.A., Vera J.C., Lacomis L., Tempst P., Golde D.W. Identification of CRKL as the constitutively phosphorylated 39-kD tyrosine phosphoprotein in chronic myelogenous leukemia cells. Blood. 84:1994;2912.
10. Oda T., Heaney C., Hagopian J., Okuda K., Griffin J.D., Druker B.J. CRKL is the major tyrosine phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J Biol Chem. 269:1994;22925.
11. ten Hoeve J., Arlinghaus R.B., Guo J.Q., Heisterkamp N. Tyrosine phosphorylation of CRKL in Philadelphia+ leukemia. Blood. 84:1994;1731.
12. Mayer B.J., Hamaguchi M., Hanafusa H. A novel viral oncogene with structural similarity to phospholipase C. Nature. 332:1988;272.
13. Matsuda M., Mayer B.J., Fukui Y., Hanafusa H. Binding of transforming protein, p47gag-crk, to a broad range of phosphotyrosine-containing proteins. Science. 248:1990;1537.
14. Heaney C., Kolibaba K., Bhat A., Oda T., Ohno S., Fanning S., Druker B.J. Direct binding of CRKL to BCR-ABL is not required for BCR-ABL transformation. Blood. 89:1997;297.
15. Feller S.M., Ren R., Hanafusa H., Baltimore D. SH2 and SH3 domains as molecular adhesives. the interactions of Crk and Abl Trends Biochem Sci. 19:1994;453.
16. Carlesso N., Frank D.A., Griffin J.D. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med. 183:1996;811.
17. Shuai K., Halpern J., ten Hoeve J., Rao X., Sawyers C.L. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene. 13:1996;247.
18. Darnell J.E. Jr. STATs and gene regulation. Science. 277:1997;1630.
19. Bhat A., Kolibaba K., Oda T., Ohno-Jones S., Heaney C., Druker B.J. Interactions of CBL with BCR-ABL and CRKL in BCR-Abl-transformed myeloid cells. J Biol Chem. 272:1997;16170.
20. Dignam J.D., Lebovitz R.M., Roeder R.G. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucl Acids Res. 11:1983;1475.
21. Kanakura Y., Druker B., Cannistra S.A., Furukawa Y., Torimoto Y., Griffin J.D. Signal transduction of the human granulocyte-macrophage colony-stimulating factor and interleukin-3 receptors involves a common set of cytoplasmic proteins. Blood. 76:1990;706.
22. Tara D., Weiss D.L., Brown M.A. Characterization of the constitutive and inducible components of a T cell IL-4 activation responsive element. J Immunol. 154:1995;4592.
23. Ricote M., Li A.C., Willson T.M., Kelly C.J., Glass C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature. 391:1998;79.
24. Yao H., Labudda K., Rim C., Capodieci P., Loda M., Stork P.J. Cyclic adenosine monophosphate can convert epidermal growth factor into a differentiating factor in neuronal cells. J Biol Chem. 270:1995;20748.
25. Avanzi G.C., Lista P., Giovinazzo B., Miniero R., Saglio G., Benetton G., Coda R., Cattoretti G., Pegoraro L. Selective growth response to IL-3 of a human leukaemic cell line with megakaryoblastic features. Br J Haematol. 69:1988;359.
26. Lozzio C.B., Lozzio B.B. Human chronic myelogenous leukemia cell line with positive Philadelphia chromosome. Blood. 45:1975;321.
27. Sattler M., Salgia R. Role of the adapter protein CRKL in signal transduction of normal hematopoietic and BCR/ABL-transformed cells. Leukemia. 12:1998;637.
28. Koval A.P., Karas M., Zick Y., LeRoith D. Interplay of the proto-oncogene proteins CrkL and CrkII in insulin-like growth factor-I receptor-mediated signal transduction. J Biol Chem. 273:1998;14780.
29. Sorokin A., Reed E., Nnkemere N., Dulin N.O., Schlessinger J. Crk protein binds to PDGF receptor and insulin receptor substrate-1 with different modulating effects on PDGF- and insulin-dependent signaling pathways. Oncogene. 16:1998;2425.
30. Yokote K., Hellman U., Ekman S., Saito Y., Ronnstrand L., Saito Y., Heldin C.H., Mori S. Identification of Tyr-762 in the platelet-derived growth factor alpha-receptor as the binding site for Crk proteins. Oncogene. 16:1998;1229.
31. Ozaki K., Oda A., Wakao H., Rhodes J., Druker B.J., Ishida A., Wakui M., Okamoto S., Morita K., Handa M., Komatsu N., Ohashi H.et al. Thrombopoietin induces association of Crkl with STAT5 but not STAT3 in human platelets. Blood. 92:1998;4652.
32. Fish E.N., Uddin S., Korkmaz M., Majchrzak B., Druker B.J., Platanias L.C. Activation of a CrkL-stat5 signaling complex by type I interferons. J Biol Chem. 274:1999;571.
33. Matsuguchi T., Salgia R., Hallek M., Eder M., Druker B., Ernst T., Griffin J.D. SHC phosphorylation in myeloid cells is regulated by GM-CSF, IL-3, and steel factor and is constitutively increased by p210BCR-ABL. J Biol Chem. 269:1994;5016.
34. Laneuville P., Heisterkamp N., Groffen J. Expression of the chronic myelogenous leukemia-associated p210bcr/abl oncoprotein in a murine IL-3 dependent myeloid cell line. Oncogene. 6:1991;275.